Movement Disorders


To address the unmet medical needs of patients suffering from hyperkinetic movement disorders, Neurocrine Biosciences developed valbenazine. Valbenazine is believed to cause reversible reduction of dopamine release at the nerve terminal by selectively inhibiting the pre-synaptic human vesicular monoamine transporter type 2 (VMAT2). In vitro, valbenazine is a selective inhibitor of human VMAT2 showing little or no affinity for VMAT1, other receptors (e.g., dopamine D2 receptors), transporters and ion channels. Neurocrine Biosciences has designed this novel compound to provide sustained, plasma and brain concentrations of the active drug to allow for once-daily dosing.